WO2025082296 - ALITRETINOIN TO REDUCE OR INHIBIT ADVANCED GLYCATION END-PRODUCTS
National phase entry is expected:
Publication Number
WO/2025/082296
Publication Date
24.04.2025
International Application No.
PCT/CN2024/124620
International Filing Date
14.10.2024
Title **
[English]
ALITRETINOIN TO REDUCE OR INHIBIT ADVANCED GLYCATION END-PRODUCTS
[French]
ALITRÉTINOÏNE SERVANT À RÉDUIRE OU INHIBER DES PRODUITS FINAUX DE GLYCATION AVANCÉE
Applicants **
NANJING NUTRABUILDING BIO-TECH CO., LTD.
Inventors
YI, Ronghua
WELLS, Shawn
LIAO, Kylin
Priority Data
PCT/CN2023/124668
16.10.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2299 | |
| EPO | Filing, Examination, Granting | 21797 | |
| Japan | Filing, Examination, Granting | 2772 | |
| South Korea | Filing, Examination, Granting | 3467 | |
| USA | Filing, Examination, Granting | 7740 |
Total:
38,075
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Methods for reducing or inhibiting advanced glycation end products (AGEs) in a subject, comprising administration to the subject a composition comprising an effective amount of alitretinoin or a pharmaceutically acceptable salt, hydrate, ester, analog or derivative thereof. A composition comprising an effective amount of alitretinoin or a pharmaceutically acceptable salt, hydrate, ester, analog or derivative thereof, for reducing or inhibiting advanced glycation end products (AGEs) in a subject.[French]
L'invention concerne des méthodes de réduction ou d'inhibition de produits finaux de glycation avancée (AGE) chez un sujet, comprenant l'administration au sujet d'une composition contenant une quantité efficace d'alitrétinoïne ou d'un sel, d'un hydrate, d'un ester, d'un analogue ou d'un dérivé pharmaceutiquement acceptable de celle-ci. L'invention concerne une composition contenant une quantité efficace d'alitrétinoïne ou d'un sel, d'un hydrate, d'un ester, d'un analogue ou d'un dérivé pharmaceutiquement acceptable de celle-ci, servant à réduire ou inhiber des produits finaux de glycation avancée (AGE) chez un sujet.